Identification

Name
Propacetamol
Accession Number
DB09288
Type
Small Molecule
Groups
Approved, Investigational
Description

Propacetamol is a non-opioid analgesic devoid of the major contraindications.[1] It is a derivative of paracetamol with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. Propacetamol is a parenteral formulation of paracetamol and thus, it is a prodrug that is completely hydrolyzed to paracetamol.[3] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[5]

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Propacetamol hydrochlorideSH41QYH8E566532-86-3WGTYJNGARJPYKG-UHFFFAOYSA-N
International/Other Brands
Pro-dafalgan
Categories
UNII
5CHW4JMR82
CAS number
66532-85-2
Weight
Average: 264.325
Monoisotopic: 264.147392512
Chemical Formula
C14H20N2O3
InChI Key
QTGAJCQTLIRCFL-UHFFFAOYSA-N
InChI
InChI=1S/C14H20N2O3/c1-4-16(5-2)10-14(18)19-13-8-6-12(7-9-13)15-11(3)17/h6-9H,4-5,10H2,1-3H3,(H,15,17)
IUPAC Name
4-acetamidophenyl 2-(diethylamino)acetate
SMILES
CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1

Pharmacology

Indication

Propacetamol is a paracetamol prodrug of intravenous administration used to control fever and pain of perioperative period in multimodal analgesia therapy.[7]

Pharmacodynamics

Propacetamol is hydrolyzed to paracetamol and then it presents a weak inhibition of COX-1 and COX-2 which is translated into a low anti-inflammatory activity. Therefore, in high inflammatory conditions, such as rheumatoid arthritis, these agents show limited in vivo suppression of inflammation and platelet activity. The formation of N-arachidonoylphenolamine, donates paracetamol with analgesic and antipyretic properties.[8]

Mechanism of action

As propacetamol is a prodrug, its mechanism of action is directly linked to the activity of paracetamol. The mechanism of action of paracetamol is described by the inhibition of prostaglandin synthesis.[7] This inhibition is attained by inhibition of COX-1 and COX-2 in an environment where arachidonic acid and peroxides are kept low.[8] It is considered that paracetamol presents a very complex mechanism of action involving effects in the peripheral system, described by direct COX inhibition; the central system, characterized by inhibition of COX, serotonergic descending neuronal pathway, L-arginine/NO pathway and cannabinoid system; and a redox mechanism.[2] In the brain and spinal cord, paracetamol can combine with arachidonic acid to form N-arachidonoylphenolamine. This metabolite is an activator of capsaicin receptor (TRPV1) and cannabinoid CB1.[8]

TargetActionsOrganism
AProstaglandin G/H synthase 1
antagonist
Human
AProstaglandin G/H synthase 2
antagonist
Human
ATransient receptor potential cation channel subfamily V member 1
antagonist
Human
ACannabinoid receptor 1
antagonist
Human
Absorption

The bioavailability of 2g of propacetamol is similar to the bioavailability found in 1 g of intravenous paracetamol. Peak plasma concentration is obtained as and from the end of infusion. Pharmacokinetic analysis with intravenous propacetamol showed a significantly higher and earlier maximum plasma concentration than orally administered paracetamol. The Cmax, Tmax and AUC are 12.72 mcg/ml, 0.25 h and 25.5 mcg.h/ml. After infusion with propacetamol, significant concentrations of paracetamol are observed in cerebrospinal fluid.[6]

Volume of distribution

The volume of distribution of propacetamol is 1.29 l/kg.[6]

Protein binding

Propacetamol is very rapidly converted into paracetamol and this later component tends to present a very negligible binding to plasma proteins.[3]

Metabolism

After administration, propacetamol is completely converted by plasma esterases into N, N-diethylglycine and paracetamol. The latest is the active metabolite. It is reported that the active metabolite of propacetamol can be transformed to N-acetil-p-benzoquinone imine by CYP2E1 which is a hepatotoxic metabolite.[7]

Route of elimination

The metabolites of propacetamol are mainly excreted in the urine. From the elimination rate, 90% of the administered dose is excreted in 24 hours mainly as glucuronide and sulfate conjugates. Less than 5% is eliminated as unchanged paracetamol.[9]

Half life

The half-life of propacetamol is of 3.6 h.[6]

Clearance

The clearance rate of propacetamol is 0.28 l.h/kg.[6]

Toxicity

The intravenous administration of paracetamol in the form of propacetamol has no effect on fertility. There is no evidence of carcinogenic potential in mice but there is a report in female rats at 0.7 times the maximum clinical exposure where there was a report of mononuclear cell leukemia. There is a potential clastogenic effect at doses of 8 times the maximum anticipated clinical exposure.[9]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Propacetamol.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Propacetamol is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Propacetamol is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Propacetamol is combined with 5-androstenedione.Experimental, Illicit
AbciximabPropacetamol may increase the anticoagulant activities of Abciximab.Approved
AcebutololPropacetamol may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolPropacetamol may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Propacetamol.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alendronic acid.Approved
AliskirenPropacetamol may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alminoprofen.Experimental
AlprenololPropacetamol may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Propacetamol.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Amcinonide.Approved
AmikacinPropacetamol may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmiloridePropacetamol may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Aminosalicylic Acid.Approved
AmiodaronePropacetamol may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AmobarbitalThe metabolism of Propacetamol can be increased when combined with Amobarbital.Approved, Illicit
AncrodPropacetamol may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Propacetamol.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Propacetamol is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Propacetamol is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Antipyrine.Approved, Investigational
Antithrombin III humanPropacetamol may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Antrafenine.Approved
ApixabanPropacetamol may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Propacetamol is combined with Apocynin.Investigational
ApramycinPropacetamol may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Propacetamol.Approved, Investigational
ArbekacinPropacetamol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinPropacetamol may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPropacetamol may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPropacetamol may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapinePropacetamol may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Atamestane.Investigational
AtenololPropacetamol may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Propacetamol.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Propacetamol.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Propacetamol is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Propacetamol.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Propacetamol.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Propacetamol can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Propacetamol can be increased when combined with Barbital.Illicit
BecaplerminPropacetamol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPropacetamol may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinPropacetamol may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Propacetamol.Approved
BenorilateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Propacetamol.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Propacetamol.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Propacetamol.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Betamethasone.Approved, Vet Approved
BetaxololPropacetamol may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Propacetamol.Approved, Investigational
BevantololPropacetamol may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Propacetamol.Approved, Investigational
BisoprololPropacetamol may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPropacetamol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPropacetamol may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bucillamine.Investigational
BucindololPropacetamol may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bufexamac.Approved, Experimental
BufuralolPropacetamol may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Propacetamol.Approved
BupranololPropacetamol may decrease the antihypertensive activities of Bupranolol.Approved
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Propacetamol.Approved, Investigational
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Propacetamol.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Propacetamol.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Captopril.Approved
CarbamazepineThe metabolism of Propacetamol can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Propacetamol is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Propacetamol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololPropacetamol may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPropacetamol may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Propacetamol.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Celecoxib.Approved, Investigational
CeliprololPropacetamol may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinPropacetamol may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Propacetamol.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Propacetamol.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Propacetamol.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cimicoxib.Investigational
CinoxacinPropacetamol may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinPropacetamol may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cisplatin.Approved
Citric AcidPropacetamol may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Propacetamol.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Propacetamol.Vet Approved
CloranololPropacetamol may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindionePropacetamol may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Propacetamol is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Propacetamol.Experimental
CyclosporinePropacetamol may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilatePropacetamol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPropacetamol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPropacetamol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPropacetamol may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the hepatotoxic activities of Propacetamol.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Propacetamol is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Propacetamol is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Delapril.Investigational
DesipraminePropacetamol may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinPropacetamol may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Propacetamol.Approved, Investigational
DextranPropacetamol may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinPropacetamol may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Propacetamol is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Propacetamol.Approved, Vet Approved
DicoumarolPropacetamol may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Propacetamol is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Propacetamol.Approved
DihydrostreptomycinPropacetamol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Propacetamol.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Propacetamol.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Propacetamol.Approved
DiphenadionePropacetamol may increase the anticoagulant activities of Diphenadione.Experimental
DrospirenonePropacetamol may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Propacetamol is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Propacetamol is combined with E-6201.Investigational
Edetic AcidPropacetamol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPropacetamol may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Propacetamol is combined with Enalaprilat.Approved
EnoxacinPropacetamol may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinPropacetamol may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Propacetamol.Experimental
EpanololPropacetamol may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Propacetamol.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Propacetamol.Experimental
EplerenonePropacetamol may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Propacetamol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Propacetamol.Approved
EquileninThe risk or severity of adverse effects can be increased when Propacetamol is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Equilin.Approved
EsatenololPropacetamol may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololPropacetamol may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Propacetamol.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Propacetamol is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ethenzamide.Experimental
Ethyl biscoumacetatePropacetamol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Propacetamol.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Propacetamol.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Propacetamol.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Propacetamol.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Propacetamol.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Feprazone.Experimental
Ferulic acidPropacetamol may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Propacetamol.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fish oil.Approved, Nutraceutical
FleroxacinPropacetamol may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Propacetamol.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fludrocortisone.Approved, Investigational
FluindionePropacetamol may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequinePropacetamol may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Propacetamol.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Propacetamol.Approved, Nutraceutical, Vet Approved
FondaparinuxPropacetamol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Propacetamol.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of the active metabolites of Propacetamol can be reduced when Propacetamol is used in combination with Fosphenytoin resulting in a loss in efficacy.Approved, Investigational
FramycetinPropacetamol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Propacetamol.Approved, Vet Approved
GabexatePropacetamol may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPropacetamol may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPropacetamol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Propacetamol.Approved, Withdrawn
GemifloxacinPropacetamol may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPropacetamol may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPropacetamol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APropacetamol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinPropacetamol may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Propacetamol is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Propacetamol is combined with HE3286.Investigational
HeparinPropacetamol may increase the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe metabolism of Propacetamol can be increased when combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Higenamine.Investigational
HydralazinePropacetamol may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Propacetamol.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Propacetamol.Approved, Investigational
Hygromycin BPropacetamol may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Propacetamol.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Propacetamol.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Propacetamol is combined with Icosapent.Approved, Nutraceutical
IdraparinuxPropacetamol may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Propacetamol.Approved, Investigational
ImatinibPropacetamol may increase the hepatotoxic activities of Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Propacetamol.Approved
IndenololPropacetamol may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Propacetamol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Propacetamol.Approved, Investigational
IsepamicinPropacetamol may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoniazidIsoniazid may increase the hepatotoxic activities of Propacetamol.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Propacetamol.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Propacetamol is combined with Istaroxime.Investigational
KanamycinPropacetamol may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Propacetamol.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Propacetamol.Approved
LabetalolPropacetamol may decrease the antihypertensive activities of Labetalol.Approved
LandiololPropacetamol may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Propacetamol.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Propacetamol.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Propacetamol.Approved, Investigational
LepirudinPropacetamol may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPropacetamol may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololPropacetamol may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololPropacetamol may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPropacetamol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Propacetamol.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Propacetamol.Experimental
LomefloxacinPropacetamol may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Propacetamol.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Propacetamol.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Propacetamol.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Propacetamol.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Propacetamol.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Propacetamol is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mefenamic acid.Approved
MelagatranPropacetamol may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Propacetamol is combined with Meloxicam.Approved, Vet Approved
MepindololPropacetamol may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Propacetamol.Approved, Investigational, Withdrawn
MethohexitalThe metabolism of Propacetamol can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Propacetamol.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Propacetamol.Approved
MethylphenobarbitalThe metabolism of Propacetamol can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPropacetamol may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Propacetamol.Approved
MetoprololPropacetamol may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetyraponeThe serum concentration of the active metabolites of Propacetamol can be increased when Propacetamol is used in combination with Metyrapone.Approved, Investigational
MicronomicinPropacetamol may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Propacetamol.Approved, Experimental
MipomersenMipomersen may increase the hepatotoxic activities of Propacetamol.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Propacetamol.Approved
MizoribineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Propacetamol.Approved
MoxifloxacinPropacetamol may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Propacetamol.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Propacetamol.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Nabumetone.Approved
NadololPropacetamol may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPropacetamol may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatPropacetamol may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Propacetamol.Approved
Nalidixic AcidPropacetamol may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Propacetamol is combined with NCX 1022.Investigational
NeaminePropacetamol may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololPropacetamol may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinPropacetamol may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPropacetamol may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Nepafenac.Approved, Investigational
NetilmicinPropacetamol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Nitroaspirin.Investigational
NorfloxacinPropacetamol may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinPropacetamol may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propacetamol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propacetamol.Approved
OlsalazinePropacetamol may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Propacetamol is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Propacetamol is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Orgotein.Vet Approved
OtamixabanPropacetamol may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Oxaprozin.Approved
Oxolinic acidPropacetamol may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPropacetamol may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Propacetamol.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Parecoxib.Approved
ParomomycinPropacetamol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Parthenolide.Approved, Investigational
PazufloxacinPropacetamol may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPropacetamol may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPropacetamol may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitratePropacetamol may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Propacetamol can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfatePropacetamol may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Perindopril.Approved
PhenindionePropacetamol may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Propacetamol can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonPropacetamol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Phenylbutazone.Approved, Vet Approved
PhenylephrineThe serum concentration of Phenylephrine can be increased when it is combined with Propacetamol.Approved
PhenytoinThe serum concentration of the active metabolites of Propacetamol can be reduced when Propacetamol is used in combination with Phenytoin resulting in a loss in efficacy.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Propacetamol.Approved, Investigational
PindololPropacetamol may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidPropacetamol may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Propacetamol.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Propacetamol.Approved, Investigational
Piromidic acidPropacetamol may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Propacetamol is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorPropacetamol may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinPropacetamol may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Propacetamol.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pomalidomide.Approved
Potassium CitratePropacetamol may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololPropacetamol may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Propacetamol.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Propacetamol can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of the active metabolites of Propacetamol can be increased when Propacetamol is used in combination with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Proglumetacin.Experimental
PropafenonePropacetamol may decrease the antihypertensive activities of Propafenone.Approved
PropranololPropacetamol may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Propacetamol.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Propacetamol.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Propacetamol.Vet Approved
Protein CPropacetamol may increase the anticoagulant activities of Protein C.Approved
Protein S humanPropacetamol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePropacetamol may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPropacetamol may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Propacetamol.Investigational
PuromycinPropacetamol may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Propacetamol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinPropacetamol may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinPropacetamol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Risedronate.Approved, Investigational
RivaroxabanPropacetamol may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinPropacetamol may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinPropacetamol may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Propacetamol.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Propacetamol.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Propacetamol.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Propacetamol.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Propacetamol.Approved, Investigational
SecobarbitalThe metabolism of Propacetamol can be increased when combined with Secobarbital.Approved, Vet Approved
SeliciclibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Propacetamol is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Propacetamol.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Propacetamol is combined with Serrapeptase.Investigational
SisomicinPropacetamol may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPropacetamol may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitratePropacetamol may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicSodium phosphate may increase the nephrotoxic activities of Propacetamol.Approved
SorafenibSorafenib may increase the hepatotoxic activities of Propacetamol.Approved, Investigational
SotalolPropacetamol may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinPropacetamol may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Spirapril.Approved
SpironolactonePropacetamol may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Propacetamol.Investigational
StreptomycinPropacetamol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Propacetamol is combined with Sulindac.Approved, Investigational
SulodexidePropacetamol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Propacetamol.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Propacetamol is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Suxibuzone.Experimental
TacrolimusPropacetamol may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Propacetamol.Approved
TalinololPropacetamol may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Propacetamol.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Propacetamol.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Propacetamol.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Propacetamol.Approved, Investigational
TemafloxacinPropacetamol may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tepoxalin.Vet Approved
TerbutalinePropacetamol may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Propacetamol.Approved
TertatololPropacetamol may decrease the antihypertensive activities of Tertatolol.Experimental
ThiamylalThe metabolism of Propacetamol can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Propacetamol can be increased when combined with Thiopental.Approved, Vet Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololPropacetamol may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tinoridine.Investigational
TioclomarolPropacetamol may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tixocortol.Approved, Withdrawn
TobramycinPropacetamol may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Propacetamol.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Propacetamol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Propacetamol.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Propacetamol.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Propacetamol.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Propacetamol is combined with Triamcinolone.Approved, Vet Approved
TriamterenePropacetamol may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Propacetamol.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Propacetamol is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Propacetamol is combined with Trolamine salicylate.Approved
TrovafloxacinPropacetamol may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinPropacetamol may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Propacetamol.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Propacetamol is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Propacetamol.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Propacetamol.Approved
WarfarinPropacetamol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPropacetamol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Propacetamol.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Propacetamol.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Propacetamol is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Propacetamol is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Propacetamol.Withdrawn
Food Interactions
Not Available

References

General References
  1. Hans P, Brichant JF, Bonhomme V, Triffaux M: Analgesic efficiency of propacetamol hydrochlorid after lumbar disc surgery. Acta Anaesthesiol Belg. 1993;44(4):129-33. [PubMed:8116325]
  2. Jozwiak-Bebenista M, Nowak JZ: Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014 Jan-Feb;71(1):11-23. [PubMed:24779190]
  3. Bannwarth B, Netter P, Lapicque F, Gillet P, Pere P, Boccard E, Royer RJ, Gaucher A: Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. Br J Clin Pharmacol. 1992 Jul;34(1):79-81. [PubMed:1633071]
  4. Allegaert K, Van der Marel CD, Debeer A, Pluim MA, Van Lingen RA, Vanhole C, Tibboel D, Devlieger H: Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F25-8. [PubMed:14711849]
  5. Anaesthesia, pain and intensive care [Link]
  6. New zealand perfalgan report [Link]
  7. Sociedade brasileira de quimica [Link]
  8. Update in anaesthesia [Link]
  9. Monograph [Link]
External Links
KEGG Drug
D07294
PubChem Compound
68865
PubChem Substance
310265180
ChemSpider
62097
ChEBI
135089
ChEMBL
CHEMBL1851805
Wikipedia
Propacetamol
ATC Codes
N02BE05 — Propacetamol
MSDS
Download (40.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedPreventionPonv / Propacetamol1
Not AvailableCompletedTreatmentProphylaxis against postoperative nausea and vomiting1
Not AvailableNot Yet RecruitingTreatmentInguinal Hernias1
Not AvailableNot Yet RecruitingTreatmentPain / Thyroidectomy1
Not AvailableRecruitingSupportive CareArrythmias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
boiling point (°C)434.5ºC at 760 mmHg'MSDS'
water solubilitySolubleOscier, Bosley and Milner. (2007). Update in Anaesthesia.
logP1.65'MSDS'
Predicted Properties
PropertyValueSource
Water Solubility0.513 mg/mLALOGPS
logP1.96ALOGPS
logP1.42ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.67ChemAxon
pKa (Strongest Basic)6.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area58.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity74.98 m3·mol-1ChemAxon
Polarizability29.17 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid esters
Alternative Parents
Phenol esters / Acetanilides / N-acetylarylamines / Phenoxy compounds / Acetamides / Trialkylamines / Secondary carboxylic acid amides / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organopnictogen compounds
show 3 more
Substituents
Alpha-amino acid ester / Acetanilide / Phenol ester / N-acetylarylamine / Anilide / Phenoxy compound / N-arylamide / Monocyclic benzene moiety / Benzenoid / Acetamide
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Update in anaesthesia [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Update in anaesthesia [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Transmembrane signaling receptor activity
Specific Function
Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular aci...
Gene Name
TRPV1
Uniprot ID
Q8NER1
Uniprot Name
Transient receptor potential cation channel subfamily V member 1
Molecular Weight
94955.33 Da
References
  1. Update in anaesthesia [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
Involved in cannabinoid-induced CNS effects. Acts by inhibiting adenylate cyclase. Could be a receptor for anandamide. Inhibits L-type Ca(2+) channel current. Isoform 2 and isoform 3 have altered l...
Gene Name
CNR1
Uniprot ID
P21554
Uniprot Name
Cannabinoid receptor 1
Molecular Weight
52857.365 Da
References
  1. Update in anaesthesia [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Allegaert K, Van der Marel CD, Debeer A, Pluim MA, Van Lingen RA, Vanhole C, Tibboel D, Devlieger H: Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F25-8. [PubMed:14711849]

Drug created on October 29, 2015 13:38 / Updated on July 02, 2018 20:44